GLP-1 receptor agonists have been shown to promote weight loss and reduce cardiovascular risk, addressing two critical concerns in women with T2DM who often face obesity and heightened cardiovascular vulnerability [28]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.